Pulse Biosciences/$PLSE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pulse Biosciences
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Ticker
$PLSE
Sector
Primary listing
Employees
116
Headquarters
Website
PLSE Metrics
BasicAdvanced
$1.4B
-
-$1.08
1.80
-
Price and volume
Market cap
$1.4B
Beta
1.8
52-week high
$26.30
52-week low
$12.56
Average daily volume
469K
Financial strength
Current ratio
10.529
Quick ratio
10.225
Long term debt to equity
7.389
Total debt to equity
9.336
Profitability
EBITDA (TTM)
-75.868
Gross margin (TTM)
-54.00%
Net profit margin (TTM)
-20,794.57%
Operating margin (TTM)
-21,982.57%
Management effectiveness
Return on assets (TTM)
-42.37%
Return on equity (TTM)
-74.45%
Valuation
Price to revenue (TTM)
4,101.675
Price to book
17.92
Price to tangible book (TTM)
18.7
Price to free cash flow (TTM)
-26.361
Free cash flow yield (TTM)
-3.79%
Free cash flow per share (TTM)
-0.808
Growth
Earnings per share change (TTM)
17.69%
3-year revenue growth (CAGR)
-20.63%
3-year earnings per share growth (CAGR)
-14.44%
10-year earnings per share growth (CAGR)
11.26%
What the Analysts think about PLSE
Analyst ratings (Buy, Hold, Sell) for Pulse Biosciences stock.
PLSE Financial Performance
Revenues and expenses
PLSE Earnings Performance
Company profitability
PLSE News
AllArticlesVideos
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Business Wire·1 week ago
Pulse Biosciences' nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting
Business Wire·1 week ago
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pulse Biosciences stock?
Pulse Biosciences (PLSE) has a market cap of $1.4B as of March 13, 2026.
What is the P/E ratio for Pulse Biosciences stock?
The price to earnings (P/E) ratio for Pulse Biosciences (PLSE) stock is 0 as of March 13, 2026.
Does Pulse Biosciences stock pay dividends?
No, Pulse Biosciences (PLSE) stock does not pay dividends to its shareholders as of March 13, 2026.
When is the next Pulse Biosciences dividend payment date?
Pulse Biosciences (PLSE) stock does not pay dividends to its shareholders.
What is the beta indicator for Pulse Biosciences?
Pulse Biosciences (PLSE) has a beta rating of 1.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.